John P. Docherty

John P. Docherty

Auto-generated profile, based on publicly available information

John P. Docherty

Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center Dr, Princeton, NJ 08540, USA; Weill Cornell Medical College, 400 E 67th St, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
EFErin Falconer
Erin Falconer
DKDavid Kho
David Kho
JDJohn P Docherty
John P Docherty
This systematic literature review investigates the use of technology for the coordination and management of mental health care with an emphasis on outcomes. Searches of MEDLINE/PubMed, Scopus, and EMBASE were conducted between January 1, 2003, and January 4, 2018, to identify articles that assessed patient outcomes associated with care coordination, evaluated technology to improve care, or discussed management of mental health care using technology. A total of 21 articles were included in a qualitative review based on the recommendations set forth by the PRISMA statement. Among the various health technologies, electronic health records were most commonly used for care coordination, with primary care being the most frequent setting. Care coordination was shown to provide easier patient access to health care providers and to improve communication between caregiver and patient, especially in cases where geographic location or distance is a challenge. Barriers to coordinated care included, but were not limited to, insufficient funding for health information technology, deficient reimbursement plans, limited access to technologies, cultural barriers, and underperforming electronic health record templates. In conclusion, many studies showed the benefit of coordinated and collaborative care through the use of technology; however, further research and development efforts are needed to continue technological innovation for advanced patient care.

12 June 2018 in JMIR Mental Health
Verified
Journal Article
Open access
AHAinslie Hatch
Ainslie Hatch
JHJulia E Hoffman
Julia E Hoffman
RRRuth Ross
Ruth Ross
JDJohn P Docherty
John P Docherty
Background: Digital technology is increasingly being used to enhance health care in various areas of medicine. In the area of serious mental illness, it is important to understand the special characteristics of target users that may influence motivation and competence to use digital health tools, as well as the resources and training necessary for these patients to facilitate the use of this technology. Objective: The aim of this study was to conduct a quantitative expert consensus survey to identify key characteristics of target users (patients and health care professionals), barriers and facilitators for appropriate use, and resources needed to optimize the use of digital health tools in patients with serious mental illness. Methods: A panel of 40 experts in digital behavioral health who met the participation criteria completed a 19-question survey, rating predefined responses on a 9-point Likert scale. Consensus was determined using a chi-square test of score distributions across three ranges (1-3, 4-6, 7-9). Categorical ratings of first, second, or third line were designated based on the lowest category into which the CI of the mean ratings fell, with a boundary >6.5 for first line. Here, we report experts’ responses to nine questions (265 options) that focused on (1) user characteristics that would promote or hinder the use of digital health tools, (2) potential benefits or motivators and barriers or unintended consequences of digital health tool use, and (3) support and training for patients and health care professionals. Results: Among patient characteristics most likely to promote use of digital health tools, experts endorsed interest in using state-of-the-art technology, availability of necessary resources, good occupational functioning, and perception of the tool as beneficial. Certain disease-associated signs and symptoms (eg, more severe symptoms, substance abuse problems, and a chaotic living situation) were considered likely to make it difficult for patients to use digital health tools. Enthusiasm among health care professionals for digital health tools and availability of staff and equipment to support their use were identified as variables to enable health care professionals to successfully incorporate digital health tools into their practices. The experts identified a number of potential benefits of and barriers to use of digital health tools by patients and health care professionals. Experts agreed that both health care professionals and patients would need to be trained in the use of these new technologies. Conclusions: These results provide guidance to the mental health field on how to optimize the development and deployment of digital health tools for patients with serious mental illness.

14 May 2025 in Journal of Affective Disorders
Verified
Journal Article
Open access
BRBrian Rothman
Brian Rothman
MSMary Slomkowski
Mary Slomkowski
ASAustin Speier
Austin Speier
ARA. John Rush
A. John Rush
MTMadhukar Trivedi
Madhukar Trivedi
AFAinslie Forbes
Ainslie Forbes
Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). This study evaluated the effectiveness and safety of a novel DTx, CT-152 (Rejoyn™), for MDD adjunctive to antidepressant medication monotherapy. Adults aged 22-64 years with MDD having an inadequate response to current antidepressant medication monotherapy were enrolled in a phase 3 multicenter, randomized, blinded, sham-controlled, remote trial with a 6-week intervention and 4-week extension. Delivered via smartphone apps, the CT-152 group received a cognitive-emotional and behavioral therapeutic intervention; the control group received a sham app with a working memory task. Both groups received supportive text messages and continued current antidepressant medication. The primary outcome was Montgomery-Åsberg Depression Rating Scale (MADRS) score change from baseline to week 6. Treatment-emergent adverse events (TEAEs) were assessed. Overall, 386 participants were randomly assigned (CT-152, n = 194; sham, n = 192). In the primary efficacy analysis of participants with ≥ 1 treatment session and ≥ 1 MADRS assessment post-baseline (n = 354), MADRS score changed -9.03 in the CT-152 group and - 7.25 in the sham (difference, - 1.78; P = 0.0568). These results were consistent with data from additional patient and clinician scales. In a supportive analysis of the intent-to-treat sample (N = 386), the between-group difference in 6-week MADRS change from baseline was -2.12 (P = 0.0211), favoring CT-152. No TEAEs or discontinuations were considered related to CT-152, and no deaths occurred. CT-152 resulted in depression symptom improvement and a favorable safety profile. Based on these data, CT-152 became the first FDA-authorized prescription DTx for the adjunctive treatment of MDD.

26 March 2024 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
RMRebecca Monachelli
Rebecca Monachelli
SDSharon Watkins Davis
Sharon Watkins Davis
ABAllison Barnard
Allison Barnard
MLMichelle Longmire
Michelle Longmire
JDJohn P Docherty
John P Docherty
IOIngrid Oakley-Girvan
Ingrid Oakley-Girvan
Maintaining user engagement with mobile health (mHealth) apps can be a challenge. Previously, we developed a conceptual model to optimize patient engagement in mHealth apps by incorporating multiple evidence-based methods, including increasing health literacy, enhancing technical competence, and improving feelings about participation in clinical trials. This viewpoint aims to report on a series of exploratory mini-experiments demonstrating the feasibility of testing our previously published engagement conceptual model. We collected data from 6 participants using an app that showed a series of educational videos and obtained additional data via questionnaires to illustrate and pilot the approach. The videos addressed 3 elements shown to relate to engagement in health care app use: increasing health literacy, enhancing technical competence, and improving positive feelings about participation in clinical trials. We measured changes in participants’ knowledge and feelings, collected feedback on the videos and content, made revisions based on this feedback, and conducted participant reassessments. The findings support the feasibility of an iterative approach to creating and refining engagement enhancements in mHealth apps. Systematically identifying the key evidence-based elements intended to be included in an app’s design and then systematically testing the implantation of each element separately until a satisfactory level of positive impact is achieved is feasible and should be incorporated into standard app design. While mHealth apps have shown promise, participants are more likely to drop out than to be retained. This viewpoint highlights the potential for mHealth researchers to test and refine mHealth apps using approaches to better engage users.

1 July 2010 in Schizophrenia Research
Verified
Journal Article
Closed access
JDJ.P. Docherty
J.P. Docherty
RBR.A. Baker
R.A. Baker
JEJ. Eudicone
J. Eudicone
SMS. Mathew
S. Mathew
RMR N Marcus
R N Marcus
RMR. Mankoski
R. Mankoski

9 November 2022 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
IOIngrid Oakley-Girvan
Ingrid Oakley-Girvan
JDJohn P Docherty
John P Docherty
This viewpoint presents a 3-phase conceptual model of the process of user engagement with eHealth apps. We also describe how knowledge gleaned from psychosocial, behavioral, and cognitive science can be incorporated into this model to enhance user engagement with an eHealth app in each phase of the engagement process.